IBRX
Companies
NASDAQ
ImmunityBio, Inc.
Health Care
$2.84
+$0.30 (+11.72%)
Price Chart
Overview
About IBRX
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.
Market Cap
$4.2B
Volume
33.2M
Avg. Volume
25.6M
P/E Ratio
-4.357143
Dividend Yield
0.00%
Employees
581.0
Company Information
Risk & Correlation Analysis
Market Correlation
2.22
High Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, IBRX shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$4.2B
Volume33.2M
P/E Ratio-4.36
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 12, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025